diagnostics

The MoU was signed in February’2021 by India

Based on cancer biomarkers, VENTANA MMR RxDx Panel helps determine which solid tumour patients may benefit from GSK immunotherapy

It aims to boost the footprints of the CNC and enable them to gain knowledge of that particular market

Will add 300+ lab partners and expand into more towns & cities in 6 months

It is targeted at both tier I and II markets

The test will identify patient’s need for ventilation or ICU facilities and help reduce stress on healthcare resources

Antigen and Antibody testing for COVID-19 will also be available at this facility

Deal includes cash consideration of Rs. 511 crores, acquisition expected to complete within three months, and will strengthen…

Aims to make India a manufacturing center for emerging market products, plans to expand product portfolio to address affordability…

Aptamer-based sensing devices called aptasensors could speed up the diagnostic process of viral infections in a rapid and accurate…